Pipelinexin
| Asset | Modality / Target | Regimen | Indication | Discovery | Pre-Clinical | FIH | POC | Pivotal |
|---|---|---|---|---|---|---|---|---|
| IN10018 Small molecular FAK inhibitor | + PLD | PROC (double-blind, placebo controlled, randomized study) |
|
|||||
| + MEKi ± IO | IO-failed NRAS melanoma Uveal melanoma |
|
||||||
| + PLD ± IO | PROC, TNBC, HNSCC |
|
||||||
| + chemotherapy + IO | IO-failed NSCLC (randomized study) |
|
||||||
| + chemotherapy + IO bispecific | Pancreatic cancer |
|
||||||
| + KRASG12C inhibitor | KRASG12CCRC and NSCLC |
|
||||||
| +3rd EGFR inhibitor | EGFR mutant NSCLC |
|
||||||
| OMTX705 | ADC Targeting FAP | Mono / Combo | Solid Tumor |
|
||||
| INES103 | Antibody Target undisclosed | Combo | Solid Tumor |
|
||||
| IN30718 | ADC Target undisclosed | Mono | Solid Tumor |
|
||||
| IN30728 | ADC Target undisclosed | Mono | Solid Tumor |
|
||||
| IN20019 | Small molecular Target undisclosed | Mono | Solid Tumor |
|
||||
Ifebemtinib
Ifebemtinib (also known as IN10018, ifebe, BI853520) is an orally administered, highly potent and selective small molecular inhibitor of the focal adhesion kinase (FAK). InxMed translational research has demonstrated the essential functions of FAK in tumor defense.
OMTX705
OMTX705 is an ADC formed by a new humanized anti-FAP mAb that has been conjugated to a novel cytolysin, TAM470, a synthetic microtubule inhibitor from the tubulysin family. IN30705 is designed to target FAP-expressing Cancer Associated Fibroblasts (CAFs) in tumor microenvironment.
NEXT GENERATION ADC
InxMed has developed ADC to address with aims of stronger, more potent ADC to overcome emerging resistance and companion biomarker test sparing.
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us：
CopyRight © 2022 InxMed All Rights Reserved.